Cardiovascular Pharmacotherapy

ESC 2025 trials

TADCLOT trial Ticagrelor wasn’t superior to BID Clopidogrel at 1 month post-PCI, with similar bleeding, but reduced MACE in the first 2 weeks.

Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO)

Pooled analysis of VICTOR and VICTORIA trials 10% reduction in the primary composite endpoint and the CV death

Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR) Among patients with HFrEF and no recent worsening, vericiguat did not reduce the risk of a composite endpoint of time to cardiovascular death or heart failure hospitalisation. Fewer cardiovascular deaths were observed in the vericiguat group than in the placebo group.